Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial

Conclusions: SCIg is well-tolerated, safe, and effective in mild to moderate MG exacerbation. Comparative safety and efficacy must be established with randomized controlled trials. Classification of evidence: This study provides Class IV evidence that in patients with mild to moderate MG exacerbation, SCIg is safe and effective in reducing MG disability measures.
Source: Neurology - Category: Neurology Authors: Tags: Outcome research, Myasthenia, All Clinical trials, Patient safety, Class IV ARTICLE Source Type: research